Meropenem Stability in Human Plasma at -20 °C: Detailed Assessment of Degradation.

degradation meropenem plasma stability

Journal

Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404

Informations de publication

Date de publication:
16 Apr 2021
Historique:
received: 15 03 2021
revised: 13 04 2021
accepted: 14 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 1 5 2021
Statut: epublish

Résumé

There are concerns about the stability of meropenem in plasma samples, even when frozen at -20 °C. Previous smaller studies suggested significant degradation of meropenem at -20 °C after 3-20 days. However, in several recent clinical studies, meropenem plasma samples were still stored at -20 °C, or the storage temperature and/or time were not mentioned in the paper. The aim of this study was to describe and model meropenem degradation in human plasma at -20 °C over 1 year. Stability of meropenem in human plasma at -20 °C was investigated at seven concentrations (0.44, 4.38, 17.5, 35.1, 52.6, 70.1, and 87.6 mg/L) representative for the range of relevant concentrations encountered in clinical practice. For each concentration, samples were stored for 0, 7, 14, 21, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224, 252, 280, 308, 336, and 364 days at -20 °C before being transferred to -80 °C until analysis. Degradation was modeled using polynomial regression analysis and artificial neural network (ANN). Meropenem showed significant degradation over time in human plasma when stored at -20 °C. Degradation was present over the whole concentration range and increased with higher concentrations until a concentration of 35.1 mg/L. Both models showed accurate prediction of meropenem degradation. In conclusion, this study provides detailed insights into the concentration-dependent degradation of meropenem in human plasma stored at -20 °C over 1 year. Meropenem in human plasma is shown to be stable at least up to approximately 80 days when stored at -20 °C. The polynomial model allows calculating original meropenem concentrations in samples stored for a known period of time at -20 °C.

Identifiants

pubmed: 33923550
pii: antibiotics10040449
doi: 10.3390/antibiotics10040449
pmc: PMC8072937
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Antimicrob Agents Chemother. 2018 Aug 27;62(9):
pubmed: 29941653
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Mar 15;864(1-2):161-7
pubmed: 18295557
Ann Pharmacother. 2017 Nov;51(11):970-975
pubmed: 28677407
J Antimicrob Chemother. 2014 May;69(5):1416-23
pubmed: 24443514
J Pharm Biomed Anal. 2017 Sep 5;143:86-93
pubmed: 28578254
Ther Drug Monit. 2019 Aug;41(4):538-543
pubmed: 31306394
Chin Med J (Engl). 2017 May 20;130(10):1139-1145
pubmed: 28485312
J Antimicrob Chemother. 2021 Jan 19;76(2):430-433
pubmed: 33094803
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Oct 15;1065-1066:50-58
pubmed: 28946125
J Pharm Biomed Anal. 2019 May 30;169:142-150
pubmed: 30861406
Int J Pharm. 2005 Jun 13;297(1-2):110-9
pubmed: 15876500
J Antimicrob Chemother. 1989 Sep;24 Suppl A:311-20
pubmed: 2808215
Antimicrob Agents Chemother. 2015 Dec;59(12):7232-9
pubmed: 26349830
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Antimicrob Agents Chemother. 2005 Apr;49(4):1337-9
pubmed: 15793108
Intensive Care Med. 2020 Jun;46(6):1127-1153
pubmed: 32383061
Crit Care Med. 2006 Jan;34(1):51-6
pubmed: 16374156
J Pharm Biomed Anal. 2019 Jun 5;170:279-284
pubmed: 30947129
Am J Kidney Dis. 2014 Jan;63(1):170-1
pubmed: 24145021
Antimicrob Agents Chemother. 2018 Mar 27;62(4):
pubmed: 29437614
Crit Care. 2019 Mar 29;23(1):104
pubmed: 30925922
Clin Chem Lab Med. 2016 Feb;54(2):265-74
pubmed: 26351928
J Antimicrob Chemother. 2009 Jul;64(1):142-50
pubmed: 19398460
Int J Pharm. 2008 Feb 28;350(1-2):95-102
pubmed: 17904314
Stat Med. 2008 Jul 10;27(15):2865-73
pubmed: 17960576

Auteurs

Matthias Gijsen (M)

Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.
Pharmacy Department, UZ Leuven, 3000 Leuven, Belgium.

Benjamin Filtjens (B)

Department of Mechanical Engineering, KU Leuven, 3000 Leuven, Belgium.
Department of Electrical Engineering (ESAT), KU Leuven, 3000 Leuven, Belgium.

Pieter Annaert (P)

Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.
BioNotus, Galileilaan 15, 2845 Niel, Belgium.

Yeghig Armoudjian (Y)

BioNotus, Galileilaan 15, 2845 Niel, Belgium.

Yves Debaveye (Y)

Laboratory for Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium.

Joost Wauters (J)

Laboratory for Clinical Infectious and Inflammatory Diseases, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.

Peter Slaets (P)

Department of Mechanical Engineering, KU Leuven, 3000 Leuven, Belgium.

Isabel Spriet (I)

Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.
Pharmacy Department, UZ Leuven, 3000 Leuven, Belgium.

Classifications MeSH